Before revision: In here presented what-if analysis we substitute a unified therapy with a ' therapy species', which is the population of heterogeneous therapies evolving accordingly to evolutionary principles.
After revision: In here presented in silico study we suggest a way how to implement the evolutionary principles into anti-cancer therapy design. We hypothesize that instead of its ongoing supervised adaptation, the therapy may be constructed as a self-sustaining evolutionary process in a dynamic fitness landscape established implicitly by evolving cancer cells, microenvironment and the therapy itself. For these purposes, we replace a unified therapy with a ' therapy species', which is the population of heterogeneous therapies evolving accordingly to evolutionary principles.